• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结合基本动力学和标准烷基化分析来筛选类先导性KRAS G12C抑制剂。

Combining Fundamental Kinetics and Standard Alkylation Assays to Prioritize Lead-Like KRAS G12C Inhibitors.

作者信息

Frommlet Alexandra, Nguyen Lan K, Saabye Matt, Endres Nicholas F, Mulvihill Melinda M, Quinn John G

机构信息

Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, California 94080, United States.

Confluence, Saint Louis, Missouri 63110, United States.

出版信息

ACS Omega. 2024 Dec 16;9(52):51508-51514. doi: 10.1021/acsomega.4c08774. eCollection 2024 Dec 31.

DOI:10.1021/acsomega.4c08774
PMID:39758649
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11696385/
Abstract

We measure the fundamental rate constants of internally discovered KRAS G12C inhibitors to demonstrate how kinetic analyses can be integrated with standard biochemical and cell-based assays for more optimal biophysical compound prioritization. In this proof-of-principle study, we characterize three irreversible covalent inhibitors targeting the mutant cysteine at the switch II binding pocket. We estimate the three fundamental kinetic rate constants ( , , ) that define the contributions of affinity and inactivation to the overall alkylation rate for a more complete biophysical characterization. These parameters are typically unavailable and are generally approximated by a single overall alkylation rate constant ( ), where the relative contributions of affinity and inactivation remain unknown. We demonstrate that the alkylation rate constant sacrifices valuable mechanistic information leading to higher risk of suboptimal compound prioritization. Estimation of the three fundamental kinetic rate constants was made possible by developing label-free surface plasmon resonance (SPR) methodologies adapted to measure transient binding using standard SPR equipment. Binding enthalpy was measured by Eyring transition state analysis, which can also benefit compound prioritization. We illustrate how these methodologies can enable more reliable prioritization of lead-like compounds when combined with standard orthogonal assays in a typical lead optimization setting.

摘要

我们测量了内部发现的KRAS G12C抑制剂的基本速率常数,以展示如何将动力学分析与标准生化和基于细胞的检测相结合,从而更优化地进行生物物理化合物的优先级排序。在这项原理验证研究中,我们表征了三种靶向开关II结合口袋处突变半胱氨酸的不可逆共价抑制剂。我们估计了定义亲和力和失活对总体烷基化速率贡献的三个基本动力学速率常数( 、 、 ),以进行更完整的生物物理表征。这些参数通常无法获得,通常由单个总体烷基化速率常数( )近似,其中亲和力和失活的相对贡献仍然未知。我们证明,烷基化速率常数牺牲了有价值的机制信息,导致次优化合物优先级排序的风险更高。通过开发适用于使用标准SPR设备测量瞬态结合的无标记表面等离子体共振(SPR)方法,可以估计三个基本动力学速率常数。通过艾林过渡态分析测量结合焓,这也有助于化合物的优先级排序。我们说明了在典型的先导优化环境中,当这些方法与标准正交检测相结合时,如何能够更可靠地对类先导化合物进行优先级排序。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53a0/11696385/50398e6695ef/ao4c08774_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53a0/11696385/3bdb0efe9cbc/ao4c08774_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53a0/11696385/efb49b758f16/ao4c08774_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53a0/11696385/4cf9d3bfa844/ao4c08774_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53a0/11696385/50398e6695ef/ao4c08774_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53a0/11696385/3bdb0efe9cbc/ao4c08774_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53a0/11696385/efb49b758f16/ao4c08774_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53a0/11696385/4cf9d3bfa844/ao4c08774_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53a0/11696385/50398e6695ef/ao4c08774_0004.jpg

相似文献

1
Combining Fundamental Kinetics and Standard Alkylation Assays to Prioritize Lead-Like KRAS G12C Inhibitors.结合基本动力学和标准烷基化分析来筛选类先导性KRAS G12C抑制剂。
ACS Omega. 2024 Dec 16;9(52):51508-51514. doi: 10.1021/acsomega.4c08774. eCollection 2024 Dec 31.
2
A rebinding-assay for measuring extreme kinetics using label-free biosensors.使用无标记生物传感器测量极限动力学的重结合分析。
Sci Rep. 2021 Apr 15;11(1):8301. doi: 10.1038/s41598-021-87880-x.
3
A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C).靶向癌症治疗的新曙光:靶向K-Ras(G12C)的小分子共价结合抑制剂
Curr Med Chem. 2025;32(4):647-677. doi: 10.2174/0109298673258913231019113814.
4
Correction to "Combining Fundamental Kinetics and Standard Alkylation Assays to Prioritize Lead-like KRAS G12C Inhibitors".对《结合基本动力学和标准烷基化分析以筛选类先导物KRAS G12C抑制剂》的勘误
ACS Omega. 2025 Mar 11;10(11):11642. doi: 10.1021/acsomega.5c01467. eCollection 2025 Mar 25.
5
Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS Inhibitors.基于机器学习的虚拟筛选探索红树林天然产物作为KRAS抑制剂。
Pharmaceuticals (Basel). 2022 May 8;15(5):584. doi: 10.3390/ph15050584.
6
Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition.致癌性 KRAS G12C:共价抑制的动力学和氧化还原特性。
J Biol Chem. 2022 Aug;298(8):102186. doi: 10.1016/j.jbc.2022.102186. Epub 2022 Jun 24.
7
Modeling receptor flexibility in the structure-based design of KRAS inhibitors.基于结构的 KRAS 抑制剂设计中的受体柔性建模。
J Comput Aided Mol Des. 2022 Aug;36(8):591-604. doi: 10.1007/s10822-022-00467-0. Epub 2022 Aug 5.
8
Decoding KRAS dynamics: Exploring the impact of mutations and inhibitor binding.解析KRAS动力学:探究突变和抑制剂结合的影响。
Arch Biochem Biophys. 2025 Feb;764:110279. doi: 10.1016/j.abb.2024.110279. Epub 2024 Dec 20.
9
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS Inhibitor.片段优化使 KRAS 开关 II 口袋可逆结合,得到强效、体内有效的 KRAS 抑制剂。
J Med Chem. 2022 Nov 10;65(21):14614-14629. doi: 10.1021/acs.jmedchem.2c01120. Epub 2022 Oct 27.
10
Contribution of Noncovalent Recognition and Reactivity to the Optimization of Covalent Inhibitors: A Case Study on KRas.非共价识别和反应性对共价抑制剂优化的贡献:以 KRas 为例。
ACS Chem Biol. 2024 Aug 16;19(8):1743-1756. doi: 10.1021/acschembio.4c00217. Epub 2024 Jul 11.

引用本文的文献

1
Application and Cross-Validation of a High-Throughput SPR Method for Characterizing Covalent Binding Ligands.用于表征共价结合配体的高通量表面等离子体共振方法的应用与交叉验证
ACS Omega. 2025 Jul 4;10(27):29637-29646. doi: 10.1021/acsomega.5c03239. eCollection 2025 Jul 15.

本文引用的文献

1
Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability.增强效力的肽拟 VHL 配体,具有改善的口服生物利用度。
J Med Chem. 2024 Jun 13;67(11):8585-8608. doi: 10.1021/acs.jmedchem.3c02203. Epub 2024 May 29.
2
Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach.使用超灵敏免疫亲和 2D-LC-MS/MS 方法评估肿瘤活检中 KRAS G12C 靶标与共价抑制剂的结合。
Anal Chem. 2022 Sep 20;94(37):12927-12933. doi: 10.1021/acs.analchem.2c03146. Epub 2022 Sep 9.
3
High-Throughput Kinetic Characterization of Irreversible Covalent Inhibitors of KRAS by Intact Protein MS and Targeted MRM.
采用完整蛋白 MS 和靶向 MRM 技术对 KRAS 不可逆共价抑制剂进行高通量动力学表征。
Anal Chem. 2022 Jan 18;94(2):1230-1239. doi: 10.1021/acs.analchem.1c04463. Epub 2022 Jan 6.
4
Mechanism-Based and Computational-Driven Covalent Drug Design.基于机制和计算驱动的共价药物设计。
J Chem Inf Model. 2021 Nov 22;61(11):5307-5311. doi: 10.1021/acs.jcim.1c01278. Epub 2021 Nov 10.
5
Enthalpy-Entropy Compensation in Biomolecular Recognition: A Computational Perspective.生物分子识别中的焓-熵补偿:计算视角
ACS Omega. 2021 Apr 20;6(17):11122-11130. doi: 10.1021/acsomega.1c00485. eCollection 2021 May 4.
6
Advances in covalent kinase inhibitors.共价激酶抑制剂的研究进展。
Chem Soc Rev. 2020 May 7;49(9):2617-2687. doi: 10.1039/c9cs00720b. Epub 2020 Mar 30.
7
A Perspective on the Kinetics of Covalent and Irreversible Inhibition.关于共价和不可逆抑制动力学的观点。
SLAS Discov. 2017 Jan;22(1):3-20. doi: 10.1177/1087057116671509. Epub 2016 Oct 5.
8
On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.关于药物与细胞靶点的双态“诱导契合”结合的不同实验表现。
Br J Pharmacol. 2016 Apr;173(8):1268-85. doi: 10.1111/bph.13445. Epub 2016 Mar 15.
9
Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.发现和降低共价不可逆酶抑制剂风险的策略。
Future Med Chem. 2010 Jun;2(6):949-64. doi: 10.4155/fmc.10.21.
10
The role of dynamic conformational ensembles in biomolecular recognition.动态构象集合在生物分子识别中的作用。
Nat Chem Biol. 2009 Nov;5(11):789-96. doi: 10.1038/nchembio.232.